The therapeutic efficacy of 225Ac-DOTATATE in neuroendocrine tumors: a preliminary meta-analysis

作者：Jiao Ma, Yang Ji, Zhihan Yao, Jiangchu Yangqing, Chunyin Zhang · 发表于：Frontiers in Oncology · 年份：2025 · DOI：10.3389/fonc.2025.1696063 · 被引用次数：4 · 研究领域：Neuroendocrine Tumor Research Advances、Lung Cancer Research Studies、Peptidase Inhibition and Analysis

Objective This meta-analysis aims to evaluate the therapeutic efficacy and toxicity of 225 Ac-DOTATATE in patients with metastatic neuroendocrine tumors (NETs). Methods This systematic review adheres to the Preferred Reporting Items for Systematic Reviews and Meta-Analysis (PRISMA) guidelines. PubMed and Embase were searched to identify studies that met the inclusion criteria. The primary endpoints were the evaluation of therapeutic efficacy through disease response rates (DRRs) and disease control rates (DCRs), and then toxicity is assessed. Additionally, a subgroup analysis was performed to evaluate the influence of prior 177 Lu-peptide receptor radionuclide therapy (PRRT) on efficacy. Results This meta-analysis included five studies involving a total of 153 patients. The results showed that the DRR following 225 Ac-DOTATATE treatment was 52% [95% confidence interval (CI): 43%–61%], and the DCR was 88% (95% CI: 81%–94%). The incidence of hematological toxicity was low at 2% (95% CI: 0.00%–5%), with only two patients experiencing Grade I–II renal toxicity, and no Grade III–IV toxicities were observed. Subgroup analysis indicated that patients who had previously received 177 Lu-PRRT treatment had a DRR of 51% (95% CI: 35%–66%) and a DCR of 90% (95% CI: 69%–100%), while 177 Lu-naive patients had a DRR of 47% (95% CI: 1%–97%) and a DCR of 89% (95% CI: 72%–100%). Conclusion Our preliminary analysis shows that 225 Ac-DOTATATE is an effective and safe treatment option for advanced...